ArticleACS omega2025
Facile Synthesis of Lecithin-Sophorolipid Liponiosomes Encapsulating SARS-CoV‑2 Proteins for Therapeutic Applications.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major structural proteins of SARS-CoV-2 (spike and nucleocapsid) hold higher immunogenicity and have the potential to offer protective immunity. However, development of a biogenic and biocompatible delivery vehicle for subunit vaccine candidates remains a critical gap. The study was aimed to synthesize and evaluate liponiosomes encapsulating SARS-CoV-2 proteins as a novel delivery system. The SARS-COV-2 nucleocapsid and spike proteins were expressed in the mammalian cell line. The purified proteins were encapsulated into novel liponiosome (based on biogenic lecithin-sophorolipid) nanoparticles using ultrasonication. The resulting nanoparticles were characterized for size, morphology, dispersity, and encapsulation using dynamic light scattering, transmission electron microscopy, and confocal microscopy. The cytotoxicity of the fabricated liponiosomes was assessed using cell culture assays. The synthesized liponiosomes demonstrated a uniform nanoscale size (100 ± 10 nm). The encapsulation efficiency was observed to be more than 95%, ensuring potential in delivery capacity. The confocal imaging confirmed the effective encapsulation of the viral proteins. The cytotoxicity analyses on cells revealed the negligible toxicity of the synthesized nanoparticles. The lecithin-sophorolipid liponiosome platform provides an eco-friendly, biocompatible delivery system for SARS-CoV-2 proteins, combining high encapsulation efficiency and nanoscale stability. This formulation shows potential for therapeutic or vaccine application.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.